ATryn

ATryn is a recombinant form of the human antithrombin protein. It is produced by transgenic goats that carry the gene for human antithrombin. The protein is extracted from the goat's milk and then purified for medical use. ATryn is used to prevent blood clots in patients with hereditary antithrombin deficiency, a rare genetic disorder that affects the body's ability to regulate blood clotting.

Medical Uses

ATryn is used to prevent thromboembolic events in patients with hereditary antithrombin deficiency. This condition is characterized by a lack of antithrombin, a protein that inhibits blood clotting. Without enough antithrombin, patients are at a high risk of developing blood clots, which can lead to life-threatening conditions such as pulmonary embolism and stroke.

ATryn is typically used in situations where there is an increased risk of blood clotting, such as surgery or childbirth. It is administered intravenously, usually over a period of several days.

Pharmacology

ATryn works by increasing the levels of antithrombin in the blood, thereby reducing the risk of blood clot formation. It is a recombinant form of human antithrombin, which means it is produced by genetically modified organisms (in this case, goats) that have been engineered to produce the human protein.

Side Effects

Common side effects of ATryn include bleeding, allergic reactions, and infusion site reactions. In rare cases, ATryn can cause serious side effects such as severe bleeding and allergic reactions that can be life-threatening.

History

ATryn was approved by the Food and Drug Administration (FDA) in 2009, making it the first drug produced by transgenic animals to be approved for use in the United States.

See Also

• Antithrombin
• Thromboembolism
• Transgenic animals in pharmacology